Abstract
Nocturnal enuresis (NE) is a combined symptom of nocturia and urinary incontinence. In this review, we aim to summarize the current literature on NE in terms of its definition, diagnosis, and management. Recommended diagnostic evaluation of NE includes a focused history and physical examination, urinalysis, and when indicated, ultrasound examination, flow rate, urine volume chart, urodynamics, and cystoscopy. Therapeutic options include lifestyle modification and medications (i.e., desmopressin and anticholinergics).
Introduction
Gaining the ability to hold urine through the night is one of the developmental neuro-motor skills of a functioning bladder.1 Nocturnal enuresis (NE) is considered a physiological finding in children less than five years of age, but is considered abnormal in adults.1 The International Continence Society (ICS) definition for NE is any unintended voiding during night-time sleep.2 This definition lacks duration and frequency. In the current literature, NE has been defined as one episode of nocturnal incontinence per six months or more3 at least one time per week4 or one per month.5
Regardless of underlying pathology, patients with NE experience discordance between bladder compliance, sphincter efficiency, and urine production overnight and often lack of awareness of a sensation to void. Many adults afflicted with NE are affected psychologically. The aim of this article is to further understand the definition, diagnosis, and management of NE.
Classification
There are two types of adult enuresis classifications (Table 1).1,2,6–8 NE can be classified chronologically (i.e., primary vs. secondary) or by symptomology (i.e., associated with lower urinary tract symptons[LUTS] or not).
Table 1.
Adult enuresis classification
| Primary NE (PNE) (positive history in childhood) | Secondary nocturnal | ||
| Chronologic classification | Persistent (PPNE) (never dry for more than six months) | Recurrent (PRNE) (dry for more than six months before adulthood recurrence) | enuresis (SNE) (no evidence of NE in childhood) |
| Symptomatic classification | Monosymptomatic NE (the only symptom is NE) | Polysymptomatic NE (NE with other LUTS) | |
LUTS: lower urinary tract symptoms; NE: nocturnal enuresis.
Epidemiology
Prevalence
In adults, the prevalence of NE has been reported as 2–3%.9–11 In females with voiding dysfunction and patients in nursing homes, the prevalence is higher, 23%12 and 39%,13 respectively. In special populations, such as patients with Down syndrome, the prevalence is 17.2%.14–16
Clinical course
The most common form of NE is persistent (PPNE; never dry for more than six months) followed by recurrent (PRNE; dry for more than six months before adulthood recurrence) then secondary (SNE).1 In general, NE is associated with a higher number of episodes overall and is less likely to resolve if diagnosed as an adult compared to childhood diagnosis.9–11 It is unclear if progression of NE into adulthood is dependent on the severity of childhood presentation or if adult NE arises de novo due to different physiological mechanisms.
Risk factors
Neurologic disease, psychiatric medications, and sleep apnea syndrome are risk factors for NE.6,12,17,18 Smoking,12 obesity,17 decreased physical activity, and hypertension18 are risk factors specifically identified in women. In men, benign prostatic hyperplasia and outlet obstruction are significantly associated with higher prevalence of secondary NE.6 Interestingly, NE in childhood does not increase enuresis risk in adulthood.19
Psychosocial consideration
There is a significantly higher incidence of anxiety, depression, chronic fatigue, and lower self-esteem in adults with NE as compared to the general population.6,15 Significant impact on psychosocial well-being has been noted in Western countries,2 Middle East countries,5 and Southeast countries.9 The relationship between psychological conditions and NE is complex. It is not fully established if these conditions result from NE or exacerbate NE.
Physiology
Pathophysiological mechanisms of nocturnal continence are outlined in Fig. 1. Briefly, through the night, a normal adult bladder can reach to volumes of 300–400 cc without needing to void due to bladder compliance and a closed outlet. Glomerular filtration typically decreases by 30% during the night and water reabsorption increases through the action of arginine-vasopressin. Thus, urine production decreases significantly.20 When one experiences increased volume of bladder to more than 300–400 cc, a central mechanism awakens the person before unintentional voiding occurs.12
Fig. 1.
Mechanisms of nocturnal continence.
Etiology
Etiologies of adult enuresis are classified as detrusor disorders, outlet issues, nocturnal diuresis, and increased sleep arousal threshold (Table 2).
Table 2.
Etiologies of adult enuresis
| Etiology | Subtype | Disease |
|---|---|---|
| Detrusor disorder | Detrusor over activity12 | Neurogenic bladder Idiopathic detrusor overactivity1,6 |
| Detrusor hypo-compliance12 | Scarred bladder Chronic infection1,6 |
|
| Outlet issues | Outlet obstruction12 | Neurogenic bladder, BPH, urethral stricture |
| Outlet incompetence12 | Neurogenic bladder Iatrogenic sphincter apparatus injury Antipsychotics |
|
| Nocturnal diuresis | Renal disorder12,20 | Chronic renal disorder Renal medullary concentration disorder (hemolytic disorders)4 Diuretics Nephrogenic diabetes insipidus |
| Central disorder | Obstructive sleep apnea syndrome*2,6 Chronic liver disease12,20 Elderly12 Central diabetes insipidus |
|
| Sleep arousal threshold disorder18 | Sleep disorder | Primary sleep disorder Elderly Alcohol, sedatives, antipsychotics |
| Reduced bladder sensation | Diabetes neuropathy |
Multifactorial NE is common and can complicate clinical diagnosis. For example, diuretic use can increase nocturnal urine output and concurrent sedative use can increase sleep arousal threshold. Similarly, psychiatric medications, such as olanzapine, clozapine, quetiapine,2,6 and risperidone21–23 can cause enuresis by several mechanisms, including increased arousal threshold, increased urine production, and decreased sphincter tone.6 Injured urinary sphincter during radical pelvic surgeries and concomitant polyuria caused by their continent pouch,6 as well as abnormal bladder and sphincter function and nocturnal polyuria in spinal cord injury2,6 are other examples of multifactorial NE.
Assessment
Initial presentation of NE is typically managed by primary care physicians. Further workup by a urologist is advised for adults presenting with complex or prolonged bothersome NE.6 Suggested urological evaluation is detailed in Table 3. Details of assessment in adult enuresis are depicted in Fig. 2.
Table 3.
Adult enuresis assessment
| Type of assessments | Indication | Assessment | Details and findings |
|---|---|---|---|
| Essential assessments | In all patients | History | Lower urinary tract symptoms, past medical and surgical history and medications1 |
| Physical examination | Focused neurological examination, digital rectal examination and bulbocavernous reflex1 | ||
| Urinalysis | To rule out urinary tract infection1 | ||
| Optional assessments | In patients with inadequate results with essential assessments | Urine flow rate (uroflow) | To screen silent obstruction or hypocontractile bladder2 |
| Frequency volume chart | To reveal daytime hidden symptoms, nocturnal polyuria, and maximum functional bladder capacity6,24 | ||
| Ultrasound of upper and lower urinary tract and post voiding residue | To evaluate upper tract damages and lower tract efficiency in urine elimination2 | ||
| Urodynamic study | Findings in SNE detrusor over activity, hypo-compliant bladder and silent bladder outlet obstruction2 Urodynamic studies have less value in PNE6,11 |
||
| Cystoscopy | In cases with bladder outlet obstruction, posterior urethral valve and urethral stricture have been the most common findings (6.7%)11 |
PNE: primary nocturnal enuresis; SNE: secondary nocturnal enuresis.
Fig. 2.
Assessment in adult enuresis. NE: nocturnal enuresis; OSA: obstructive sleep apnea; UDS: urodynamic study.
Management
Psychosocial stress and bothersome NE episodes typically prompt treatment. First-line treatment options include lifestyle modifications, behavioral therapy, and medical therapy. Other interventions, such as surgical intervention, neuromodulation, and botulinum toxin injection to bladder have been used in some patients but are typically reserved as second-line modalities.
Lifestyle modification
Caffeine and sedative avoidance are suggested, as they alter sleep cycle function. Alcohol avoidance is suggested due to its effect as a diuretic. Weight reduction can be advantageous through its effects of improving sleep apnea syndrome. Regular physical activity is another potential ways to decrease episodes of NE.13,18
Behavioral therapy
Although there is data to support timed voiding every two hours and alarm systems for NE in children24 there is no data in young adults. Furthermore, timed voiding has a limited role in elderly patients with NE due to decreased adaptive conditioning skills and effect on sleep disturbances.13,24 Unfortunately, compliance with enuresis alarm systems is low in the adult population, with a high withdrawal rate;4,6 however, when desmopressin failed to control enuresis, adding an alarm system has been reported to increase the response rate by 33%.2
Adapted dry behavioral therapy (ADBT) is a cognitive behavioral and prompted voiding therapy that includes close observation during sleep, waking up frequently during the night (every hour), alarm use, and day-time timed voiding. Although it is effective, high cost and time commitment commonly deter its use.25
Despite successful results in children, behavioral therapy is not as effective in adults.6 In selected adult cases (infrequent bed wetting, normal sonography, and cystometric capacity greater than 300 cc), it may have a contributive role.25
Specific treatments
First-line therapy after lifestyle changes and behavioral therapy includes treating identifiable pathologies (Fig. 3). In addition to specific therapy, any psychiatric contributors, such as depression and anxiety, should be addressed as well.15
Fig. 3.
Specific therapy for adult enuresis. *Possible explanation for decreasing nocturnal enuresis (NE) after mid-urethral sling placement is prevention of urinary leakage to proximal urethra and stress induced overactivity.12 ^Higher severity of enuresis in hemolytic disorders is associated with increased admission; therefore, efforts to manage chronic disease may help manage and better treat NE. #Although in nocturnal diuresis due to overproduction, desmopressin is treatment of choice, one should be cautioned in patients with kidney and liver disease, water intoxication, and hyponatremia; these should also be individually addressed. !Multifactorial NE is difficult to treat and best controlled by multimodal approaches and addressing all contributing etiologies.2,6 For example, empirically patients with spinal cord injury and neo-bladder after radical pelvic surgeries are managed by low-dose desmopressin, oxybutynin 5 mg three times a day, and catheterization before sleep.2 BPH: benign prostatic hyerplasia; OSA: obstructive sleep apnea.
Medical therapy
In patients with NE with no defined etiology, medical therapy is first-line. There are two classes of medications with supportive evidence: desmopressin and anticholinergics.
Desmopressin
Desmopressin has been accepted as first-line therapy of idiopathic adult NE.2 Although some authors advocate to prescribe it only in the nocturnal polyuria variant of enuresis,3 currently, it is the first treatment in adult NE with or without nocturnal polyuria.2,5
Most patients require at least 0.2–0.4 mg of desmopressin per night;2,6 physicians should start at the low dose and titrate up. Patients with detrusor overactivity often require the higher dose (0.4 mg/day) to show any benefit.5 Once the suitable dose is found, decreasing or withdrawing drug invariably causes symptom relapse and is, therefore, not recommended.5 Informing the patient about needing long-term therapy and the likelihood of decreasing the dose, as well as safety of long-term usage of the drug should be highlighted during discussion before starting desmopressin.3,5,26 Water intoxication and hyponatremia are dangerous and life-threatening complications. Fluid restriction from evening until morning is an efficient method to prevent these adverse effects. These complications are more common in the elderly. It is wise to verify serum sodium levels at short intervals in the first weeks of treatment.26
Anticholinergics
In desmopressin non-responders, an anticholinergic medication can be added. In general, there is good evidence for the safety of anticholinergics, with urinary retention being a very rare side effect, especially for the younger population with NE.5 Imipramine as a peripheral anticholinergic and a drug with possible central effects has been shown to be effective in NE with polyuria. However, there are concerns about its cardiac adverse effects in elderly patients.6 Watchful monitoring for urinary retention is important in patients using anticholinergics.
Combination therapy is a long-term and safe step in enuresis control. Discontinuation or decreasing dosage of drugs will often lead to symptom recurrence.5 If desmopressin and an anticholinergic are not effective, imipramine 25–50 mg per day has demonstrated benefit, but is uncommonly prescribed by urologists due to need for ongoing close followup and poor compliance due to sexual side effects.6
The flow of treatment steps for idiopathic nocturnal enuresis is outlined in Fig. 4.
Fig. 4.
Treatment steps for idiopathic nocturnal enuresis.
Other treatments
Minimal data exists to support surgical intervention for mono-symptomatic NE.12 Neuromodulation (peripheral and sacral) and botulinum toxin injection are capable of decreasing NE in patients with non-mono-symptomatic NE, however, there is no data supporting their use I mono-symptomatic NE.2
One randomized clinical study with 14 patients with refractory mono-symptomatic NE and abnormal detrusor function (overactivity and reduced compliance) in each group has reported significant improvement in the posterior tibial nerve stimulation arm in comparison to placebo.27
Conclusions
NE is a symptom of urinary tract disorder or systemic disease. It requires a standard evaluation consisting of history and physical exam, urinalysis, and when indicated, urinary ultrasonography, urine flow rate, frequency volume chart, urodynamic study, and cystoscopy. It is recommended that general practitioners refer adults with NE to a urologist for this workup because of its complexity.
There is minimal role for surgical intervention for this disease except in specific populations. However, many patients benefit from long-term desmopressin. Anticholinergics can add benefit even in the absence of overactive bladder symptoms. The role of neuromodulation, onabotulinumtoxin A, and surgery are undefined in the literature. Behavioral techniques offer low-risk intervention, but their time commitment is considerable and they require a high degree of commitment on behalf of the patient to ensure compliance. Future studies should address these shortfalls in the literature to better manage adult patients with NE.
Footnotes
This paper has been peer-reviewed.
To answer the multiple-choice questions associated with this article, go to: www.cuasection3credits.org/cuajaugust2019. This program is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by the Canadian Urological Association. Remember to visit MAINPORT (www.mainport.org/mainport/) to record your learning and outcomes. You may claim a maximum of 1 hour of credit.
Competing interests: Dr. Kavanagh has been an advisory board member for Paladin Labs and received a research grant from Astellas. The remaining authors report no competing personal or financial interests related to this work.
References
- 1.Sakamoto K, Blavias GB. Adult onset nocturnal enuresis. J Urol. 2001;165:1914–7. doi: 10.1097/00005392-200106000-00017. [DOI] [PubMed] [Google Scholar]
- 2.Hillary CJ, Chapple C. The evaluation and treatment of adult nocturnal enuresis. Curr Bladder Dysfunct Rep. 2014;9:84–9. doi: 10.1007/s11884-014-0237-8. [DOI] [Google Scholar]
- 3.Baek M, Park K, Lee HE, et al. Korean Children’s Continence and Enuresis Society. A nationwide epidemiological study of nocturnal enuresis in Korean adolescents and adults: Population-based, cross-sectional study. J Korean Med Sci. 2013;28:1065–70. doi: 10.3346/jkms.2013.28.7.1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Ekinci O, Celik T, Unal S, et al. Nocturnal enuresis in sickle cell disease and thalassemia major: Associated factors in a clinical sample. Int J Hematol. 2013;98:430–6. doi: 10.1007/s12185-013-1422-9. [DOI] [PubMed] [Google Scholar]
- 5.Yucel S, Ktlu O, Kukul E, et al. Impact of urodynamics in treatment of primary nocturnal enuresis persisting into adulthood. Urology. 2004;64:1020–5. doi: 10.1016/j.urology.2004.06.067. [DOI] [PubMed] [Google Scholar]
- 6.Abeygunasekera AM, Goonesinghe SK. Nocturnal enuresis in adults. Curr Bladder Dysfunct Rep. 2013;8:217–22. doi: 10.1007/s11884-013-0193-8. [DOI] [Google Scholar]
- 7.Bower WF, Sit FKY, Yeung CK. Nocturnal enuresis in adolescents and adults is associated with childhood elimination symptoms. J Urol. 2006;176:1771–5. doi: 10.1016/j.juro.2006.04.087. [DOI] [PubMed] [Google Scholar]
- 8.Lee D, Dillon B, Lemack G. Adult onset nocturnal enuresis: Identifying causes, cofactors and impact on quality of life. Low Urin Tract Symptoms. 2017;10:292–6. doi: 10.1111/luts.12183. [DOI] [PubMed] [Google Scholar]
- 9.Yeung CK, Sihoe JD, Sit FK, et al. Characteristics of primary nocturnal enuresis in adults: An epidemiological study. BJU Int. 2004;93:341–5. doi: 10.1111/j.1464-410X.2003.04612.x. [DOI] [PubMed] [Google Scholar]
- 10.Field JJ, Austin PF, An P, et al. Enuresis is a common and persistent problem among children and young adults with sickle cell anemia. Urology. 2008;72:81–4. doi: 10.1016/j.urology.2008.02.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yeung CK, Sihoe JD, Sit FK, et al. Urodynamic findings in adults with primary nocturnal enuresis. J Urol. 2004;171:2595–8. doi: 10.1097/01.ju.0000112790.72612.0a. [DOI] [PubMed] [Google Scholar]
- 12.Campbell P, Li W, Money-Taylor J, et al. Nocturnal enuresis: prevalence and associated LUTS in adult women attending a urogynecology clinic. Int Urogynecol J. 2017;28:315–20. doi: 10.1007/s00192-016-3099-0. [DOI] [PubMed] [Google Scholar]
- 13.Howlett M, Gibson W, Hunter KF, et al. Nocturnal enuresis in older people: Where is the evidence and what are the gaps? J Wound Ostomy Continence Nurs. 2016;43:401–6. doi: 10.1097/WON.0000000000000234. [DOI] [PubMed] [Google Scholar]
- 14.Niemczyk J, von Gontard A, Equit M, et al. Incontinence in persons with Down syndrome. Neurourol Urodyn. 2017;36:1550–6. doi: 10.1002/nau.23146. [DOI] [PubMed] [Google Scholar]
- 15.Guragac A, Yilmaz S, Aydur E. Mental and psychological characteristics of young adult males with primary nocturnal enuresis: A case-control observational study. Eur Urol. 2016;15:e540. doi: 10.1016/S1569-9056(16)60542-0. [DOI] [Google Scholar]
- 16.Hyde TM, Deep-Soboslay A, Iglesias B, et al. Enuresis as a premorbid developmental marker of schizophrenia. Brain. 2008;131:2489–98. doi: 10.1093/brain/awn167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Madhu CK, Hashim H, Enki D, et al. Risk factors and functional abnormalities associated with adult onset secondary nocturnal enuresis in women. Neurourol Urodyn. 2017;36:188–91. doi: 10.1002/nau.22912. [DOI] [PubMed] [Google Scholar]
- 18.Koo P, McCool FD, Hale L, et al. Association of obstructive sleep apnea risk factors with nocturnal enuresis in postmenopausal women. Menopause. 2016;23:175–82. doi: 10.1097/GME.0000000000000517. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.D’Ancona CAL, Lopes MHBM, Faleiros-Martins AC, et al. Childhood enuresis is a risk factor for bladder dysfunction in adult life? Neurourol Urodyn. 2012;31:634–6. doi: 10.1002/nau.21195. [DOI] [PubMed] [Google Scholar]
- 20.Noh JY, Han DH, Yoon JA, et al. Circadian rhythms in urinary functions: Possible roles of circadian clocks? Int Neurourol J. 2011;15:64–73. doi: 10.5213/inj.2011.15.2.64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Sunbul EA, Kosker SD, Cengiz FF, et al. Risperidone-induced enuresis nocturna. J Mood Dis. 2014;4:189–90. doi: 10.5455/jmood.20140313083641. [DOI] [Google Scholar]
- 22.Harrison-Woolrych M, Skegg K, Ashton J, et al. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine, and quetiapine: Comparative cohort study. Br J Psychiatry. 2011;199:140–4. doi: 10.1192/bjp.bp.110.087478. [DOI] [PubMed] [Google Scholar]
- 23.Lopes R, Matias J, de Melo RC. Trazodone-induced nocturnal enuresis. Psychiatry Res. 2016;235:211–2. doi: 10.1016/j.psychres.2015.12.006. [DOI] [PubMed] [Google Scholar]
- 24.Ouslander JG, Al-Samarrai N, Schnelle JF. Prompted voiding for nighttime incontinence in nursing homes: Is it effective? J Am Geriatr Soc. 2001;49:706–9. doi: 10.1046/j.1532-5415.2001.49145.x. [DOI] [PubMed] [Google Scholar]
- 25.HofmeesterI, Brinker AE, Steffens MG, et al. Reference values for frequency volume chart and uroflowmetry parameters in adolescent and adult enuresis patients. Neurourol Urodyn. 2017;36:463–8. doi: 10.1002/nau.22955. [DOI] [PubMed] [Google Scholar]
- 26.Osterberg O, Savic RM, Karlsson MO, et al. Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol. 2006;46:1204–11. doi: 10.1177/0091270006291838. [DOI] [PubMed] [Google Scholar]
- 27.Raheem AA, Farahat Y, El-Gamal O, et al. Role of posterior tibial nerve stimulation in the treatment of refractory monosymptomatic nocturnal enuresis: A pilot study. J Urol. 2013;189:1514–8. doi: 10.1016/j.juro.2012.10.059. [DOI] [PubMed] [Google Scholar]




